Please assess the completion status of the following clinical trial:

Trial Title: A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001]

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who completed 5-day repeated administrations and the follow-up observation in the preceding study (156-04-001)~* Patients in whom the safety of repeated administration was confirmed based on the investigator's reports from the preceding study (156-04-001)~Exclusion Criteria:~* Patients with serum creatinine concentration of 2.5 mg/dL or higher at the screening examination~* Patients with any of the following complications~  * Uncontrolled hypertension~ * Serious cardiovascular disease (eg. heart failure) or hepatic disease (eg. cirrhosis)~* Patients with any of the following complications or history thereof~  * Clinically significant drug allergies (anaphylaxis) or hypersensitivity (especially, hypersensitivity to benzazepine derivatives or suspected hypersensitivity thereto)~ * Inability to personally give consent due to a mental disease ~* Patients with SBP (in sitting position) \<90 mm Hg (at screening examination)~* Patients with history of massive bleeding or bleeding tendency~* Patients with a history of drug or alcohol abuse within 6 months prior to the screening examination~* Pregnant women, lactating women, or women who may become or plan to become pregnant~* Patients who received any investigational drug other than OPC-41061 within 30 days prior to commencement of administration of OPC-41061~* Any patient who, in the opinion of the principle investigator or attending investigators, should not participate in the study

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).